Evidence map›Paper›PMID 41127534›Full record

ArticleVascular health and risk management2025

Changes and Diagnostic Value of Serum CCL26 and CCR3 in T2DM with Lower Extremity Artery Disease.

Xuyan Zhang, Ting Jia, Li Li, Xiaowan Jiang, Mengjie Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vascular health and risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xuyan Zhang *Department of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.ORCID 0009-0005-0410-5605
Ting Jia *Department of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
Li LiDepartment of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
Xiaowan JiangDepartment of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
Mengjie WangDepartment of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the serum levels of Chemokine CCL26 (CCL26) and Receptors, CCR3 (CCR3) in patients with Diabetes Mellitus, Type 2 (T2DM) complicated by lower extremity artery disease (LEAD), and to evaluate their potential as diagnostic biomarkers for T2DM with LEAD. Methods: A retrospective study was conducted involving 197 patients with T2DM between June 2022 and February 2025. Patients were divided into T2DM group (n=157) and LEAD group (n=40). Clinical data and fasting venous blood were collected to measure serum CCL26 and CCR3 levels. Pearson correlation analysis was used to assess the correlation between CCL26 and CCR3. Lasso regression and logistic regression models were employed to identify risk factors for LEAD. The receiver operating characteristic (ROC) curve was constructed to evaluate the predictive efficacy of CCL26 and CCR3 for LEAD. Results: The LEAD group had significantly higher BMI, disease duration, HbA1C, FINS, and HOMA-IR compared to the T2DM group ( Conclusion: Serum CCL26 and CCR3 levels are elevated in T2DM patients with LEAD and are closely associated with its occurrence. Combined detection of these biomarkers shows good predictive value for LEAD in T2DM patients.

Indexed as

Chemokine CCL26Diabetes Mellitus, Type 2Diabetic AngiopathiesLower ExtremityPeripheral Arterial DiseaseReceptors, CCR3AgedBiomarkersFemaleHumansMaleMiddle AgedPredictive Value of TestsRetrospective StudiesRisk FactorsUp-RegulationBiomarkersCCL26 protein, humanCCR3 protein, humanChemokine CCL26Receptors, CCR3CCR3chemokine CCL26diabetes mellitusperipheral arterial diseasereceptorstype 2

Identifiers

PMID41127534
PMCPMC12537803

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.